Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AO-252 in Advanced Solid Tumors With or Without Brain Metastases
NCT06136884Phase 1Recruiting
- Sponsor
- A2A Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AO-252 in solid tumor and brain metastasis (BM) (2 arms), sponsored by A2A Pharmaceuticals. Primary endpoint: Safety Assessments at 30 months. Started Nov 2023; status: recruiting.
02
Drugs
AO-252
03
Conditions
solid tumorbrain metastasis (BM)
Beyond the preview
Go deeper on NCT06136884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136884.